Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD

In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2015-08, Vol.50 (8), p.1105
Hauptverfasser: Dhedin, N, de Latour, Rp, de Fontbrune, F. Sicre, Manene, D, Kapel, N, Xhaard, A, Robin, M, O'Meara, A, Socie, G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and [alpha]1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and [alpha]1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. [alpha]1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD. Bone Marrow Transplantation (2015) 50, 1105-1109; doi: 10.1038/bmt.2015.109; published online 11 May 2015
ISSN:0268-3369
1476-5365
DOI:10.1038/bmt.2015.109